ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Genzyme will spend some $335 million to build a manufacturing plant at its Geel, Belgium, site for alglucosidase alfa, the active ingredient in an enzyme replacement therapy that FDA approved last year for Pompe disease. The plant will include two 4,000-L bioreactors, bringing the number of bioreactors dedicated to the enzyme to five. About 150 jobs will be added to the 450 positions already at the site. Last year, Genzyme paid the U.S. government a $175 million fine because of problems at its enzyme plant in Allston, Mass.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter